Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Consumer services tags : Therapeutics save search
Principal Investigator from City of Hope National Medical Center Invited to Present Clinical Data from Marker Therapeutics APOLLO Study at 11th Global Summit on Hematologic Malignancies
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -5.73%
H: 5.86%
C: 2.17%
hope city global medical therapeutics study
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
Published: 2024-03-25 (Crawled : 22:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -0.83%
H: 2.29%
C: -10.0%
therapeutics financial results
Marker Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Published: 2024-03-22 (Crawled : 17:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: 2.06%
H: 3.68%
C: 3.68%
conference cell therapeutics therapy
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors
Published: 2024-03-12 (Crawled : 17:00) - biospace.com/
PLRX | $13.55 -4.24% -4.43% 270K
|
Health Technology
|
| O: 0.0%
H: 6.88%
C: 4.2%
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -1.2%
H: 4.88%
C: 3.17%
therapeutics
Marker Therapeutics Receives Approval from United States Adopted Name (USAN) Council and International Nonproprietary Names (INN) Expert Committee for “Neldaleucel” as Nonproprietary Name for MT-601
Published: 2024-01-22 (Crawled : 12:30) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: 1.62%
H: 8.66%
C: 3.87%
mt-601 approval international therapeutics
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
Published: 2024-01-08 (Crawled : 14:30) - biospace.com/
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -1.87%
H: 7.82%
C: 4.44%
pipeline program therapeutics
Marker Therapeutics Announces Participation in Biotech Showcase and the 19th Annual Non-Dilutive Funding Summit During “J.P. Morgan Week 2024”
Published: 2023-12-21 (Crawled : 16:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -1.04%
H: 10.24%
C: 4.72%
biotech week therapeutics funding
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
Published: 2023-12-11 (Crawled : 12:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: 3.2%
H: 46.53%
C: 42.3%
mt-601 first therapeutics response
Delisting of Securities of Genesis Growth Tech Acquisition Corp.; Financial Strategies Acquisition Corp.; Kiromic BioPharma, Inc.; Infinity Pharmaceuticals, Inc.; Molekule Group, Inc.; EBET, Inc.; Shift Technologies, Inc.; Ontrak, Inc.; RVL Pharmaceuticals plc; Biocept, Inc.; Akumin Inc.; Appreciate Holdings, Inc.; Liberty TripAdvisor Holdings, Inc.; Tempo Automation Holdings, Inc.; Medicenna Therapeutics Corp.; RiceBran Technologies; and Acer Therapeutics Inc. from The Nasdaq Stock Market
Published: 2023-11-17 (Crawled : 21:00) - globenewswire.com
FXCO | $11.0 0.91% 2.7K
|
n/a
| Email alert
Add to watchlist
INFI | $0.016 12.5% 1.1M
|
Health Technology
| Email alert
Add to watchlist
LTRPA | $1.51 5.37% 140K
|
Consumer Services
| Email alert
Add to watchlist
NDAQ | $60.2 -2.15% -2.19% 3.2M
|
Finance
| Email alert
Add to watchlist
AKU | $0.2887 -0.42% 8.5M
|
Health Services
| Email alert
Add to watchlist
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
| Email alert
Add to watchlist
MDNAF | $1.42 -18.15% 210K
|
n/a
| Email alert
Add to watchlist
BIOC | $0.4349 -10.32% 750K
|
Health Services
| Email alert
Add to watchlist
RIBT 4 | $0.138 -12.78% 8.1K
|
Consumer Non-Durables
| Email alert
Add to watchlist
OTRK J | $0.4283 9.82% 8.94% 2.7M
|
Health Services
| Email alert
Add to watchlist
LTRPB | $10.5 -27.62% 53K
|
Consumer Services
| Email alert
Add to watchlist
RVLP | $0.0282 -20.92% 64M
|
Manufacturing
| Email alert
Add to watchlist
ACER | $0.9 -3.61% 420K
|
Health Technology
| Email alert
Add to watchlist
INFIQ | $0.0001 3000.0% 680
|
Manufacturing
| Email alert
Add to watchlist
SFT | $0.1703 -23.66% 180M
|
Finance
| Email alert
Add to watchlist
KRBP | $2.939 -90.21% 320
|
Health Technology
| Email alert
Add to watchlist
GGAA | $21.57 2.1M
|
n/a
| Email alert
Add to watchlist
tempo acquisition pharmaceuticals liberty therapeutics financial growth market
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
Published: 2023-11-09 (Crawled : 22:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -5.6%
H: 5.53%
C: -3.13%
business therapeutics financial results
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
Published: 2023-09-11 (Crawled : 11:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: 8.88%
H: 13.14%
C: 2.33%
mt-601 therapeutics response
Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Published: 2023-08-30 (Crawled : 12:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -2.19%
H: 11.85%
C: 9.14%
conference global therapeutics
Marker Therapeutics Highlights Its Technology During a WBB Research Institute Webinar on CAR-T and Other Cell Therapies
Published: 2023-08-17 (Crawled : 15:00) - biospace.com/
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -1.54%
H: 4.53%
C: -1.56%
institute cell research car-t technology therapeutics
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Published: 2023-08-14 (Crawled : 21:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: 9.01%
H: 21.65%
C: 15.35%
business update therapeutics financial results
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
Published: 2023-08-07 (Crawled : 11:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -1.74%
H: 4.72%
C: -2.17%
mt-401 update program therapeutics
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
Published: 2023-07-26 (Crawled : 11:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: 1.14%
H: 9.01%
C: -3.94%
cell car-t therapeutics
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
Published: 2023-07-10 (Crawled : 11:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -2.53%
H: 30.26%
C: 26.24%
mt-401 drug treatment designation aml grants therapeutics
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
Published: 2023-06-26 (Crawled : 11:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: -5.65%
H: 2.74%
C: -1.0%
mt-401 aml therapeutics
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
Published: 2023-06-12 (Crawled : 11:00) - globenewswire.com
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: 3.98%
H: 33.33%
C: 14.94%
mt-601 trial therapeutics
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma CellsMT-601 showed anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro
Published: 2023-05-31 (Crawled : 11:00) - biospace.com/
MRKR | $4.32 0.23% 0.23% 32K
|
Consumer Services
|
| O: 39.11%
H: 5.41%
C: -3.78%
mt-601 candidate pre-clinical cell cd19 therapeutics in vitro
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.